Robert J.  Decker net worth and biography

Robert Decker Biography and Net Worth

Robert J. Decker holds the position of Chief Accounting Officer of Johnson & Johnson.

Mr. Decker received an undergraduate degree from Rider University.

What is Robert J. Decker's net worth?

The estimated net worth of Robert J. Decker is at least $2.25 million as of November 18th, 2022. Mr. Decker owns 15,473 shares of Johnson & Johnson stock worth more than $2,253,642 as of June 19th. This net worth estimate does not reflect any other investments that Mr. Decker may own. Learn More about Robert J. Decker's net worth.

How old is Robert J. Decker?

Mr. Decker is currently 52 years old. There are 6 older executives and no younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Dr. John C. Reed M.D., Ph.D., Executive Vice President of Innovative Medicine, R&D, who is 66 years old. Learn More on Robert J. Decker's age.

How do I contact Robert J. Decker?

The corporate mailing address for Mr. Decker and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on Robert J. Decker's contact information.

Has Robert J. Decker been buying or selling shares of Johnson & Johnson?

Robert J. Decker has not been actively trading shares of Johnson & Johnson during the last quarter. Most recently, Robert J. Decker sold 16,928 shares of the business's stock in a transaction on Friday, November 18th. The shares were sold at an average price of $175.00, for a transaction totalling $2,962,400.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company's stock, valued at $2,707,775. Learn More on Robert J. Decker's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (Insider), Jennifer Taubert (EVP), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 4 times. They sold a total of 97,820 shares worth more than $15,312,567.44. The most recent insider tranaction occured on February, 16th when Major Shareholder & Johnson Johnson sold 3,725 shares worth more than $96,142.25. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 2/16/2024.

Robert J. Decker Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2022Sell16,928$175.00$2,962,400.0015,473View SEC Filing Icon  
5/26/2022Sell8,462$180.00$1,523,160.0015,473View SEC Filing Icon  
12/7/2021Sell5,000$163.21$816,050.00View SEC Filing Icon  
See Full Table

Robert J. Decker Buying and Selling Activity at Johnson & Johnson

This chart shows Robert J Decker's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $145.65
Low: $145.27
High: $146.39

50 Day Range

MA: $148.13
Low: $144.40
High: $154.68

2 Week Range

Now: $145.65
Low: $143.13
High: $175.97


6,034,697 shs

Average Volume

6,944,967 shs

Market Capitalization

$350.53 billion

P/E Ratio


Dividend Yield